CClinicalTrials.gg
Sign In
Not yet recruitingNCT07364396CRC01-02Updated Jan 23, 2026

Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus

A Phase 1/2 interventional study of CRC01 in Lupus Nephritis, Lupus Nephritis (LN) and SLE, sponsored by Curocell Inc.. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Curocell Inc. · Phase 1/2, Interventional, and Treatment

Phase
Phase 1/2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Study summary

The purpose of this clinical trial is to evaluate the safety and efficacy of CRC01, an investigational autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy, in people with lupus nephritis (LN), a serious kidney complication of systemic lupus erythematosus (SLE).

The main objectives of the study are:

  1. To determine whether CRC01 infusion can improve kidney outcomes and reduce disease activity in participants with lupus nephritis.
  2. To assess the safety profile, including potential risks such as cytokine release syndrome (CRS) and neurotoxicity.

Study Design This is a single-arm, open-label, multi-center, Phase 1/2 study. All enrolled participants will receive CRC01 after screening and baseline assessments.

Study Procedures

Participants will:

  • Undergo eligibility screening, including blood tests, urine tests, and disease activity assessments.
  • Provide autologous T lymphocytes through a procedure called leukapheresis.
  • Receive a lymphodepleting pre-conditioning regimen (short course of chemotherapy).
  • Receive a single intravenous infusion of CRC01 cells.
  • Be hospitalized for close monitoring to detect and manage early adverse events such as CRS or neurotoxicity.
  • Return for scheduled follow-up assessments through Week 52 (12 months) post-infusion to evaluate safety and treatment response.

Key Outcomes

Researchers will measure:

  • Changes in proteinuria and kidney function.
  • Changes in disease activity scores.
  • Incidence and severity of adverse events.
02

Conditions studied

  • Lupus Nephritis
  • Lupus Nephritis (LN)
  • SLE
  • SLE (Systemic Lupus)
03

In context

Lupus Nephritis

331 studies on the registry are indexed under Lupus Nephritis; 131 are open to participants now.

This study's planned enrollment of 39 is below the median of 48 across 231 interventional studies indexed under Lupus Nephritis.

Browse Lupus Nephritis studies →

Lead sponsor

Curocell Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Age 19 years or older, voluntarily provides written informed consent.
  • Diagnosis of systemic lupus erythematosus (SLE) according to the 2019 EULAR/ACR classification criteria.
  • Positive antinuclear antibody (ANA) at screening (titer ≥1:80).
  • Diagnosis of lupus nephritis Class III or IV (with or without concurrent Class V), confirmed by kidney biopsy within 1 year prior to screening based on ISN/RPS 2018 criteria.
  • Inadequate response to, or intolerance of, at least two or more standard therapies for 6 months or longer (cyclophosphamide, mycophenolate mofetil, azathioprine, tacrolimus, rituximab, belimumab).
  • Proteinuria at screening with urine protein-to-creatinine ratio (UPCR) >1.5.
  • Adequate laboratory values at screening: Hemoglobin >8.0 g/dL; ANC >1,000/μL; Platelets ≥50,000/μL; Total bilirubin ≤2.0 × ULN; AST and ALT ≤3 × ULN; eGFR ≥30 mL/min/1.73 m².
  • Hemodynamically stable, no pericardial effusion, and LVEF ≥50% by echocardiogram at screening.
  • FEV1/FVC ≥70% at screening.
  • Willing and able to comply with study visits, procedures, and requirements.
  • Women of childbearing potential and men must agree to use effective contraception for at least 1 year after CRC01 infusion until PCR testing confirms clearance of CRC01.

Exclusion Criteria:

  • Current or anticipated requirement for renal dialysis during the study.
  • History of kidney transplantation or planned transplantation during the study.
  • History of severe CNS lupus or currently active severe CNS lupus.
  • Prior CAR-T cell therapy.
  • History of malignancy except for: basal or squamous cell carcinoma of skin treated and disease-free ≥3 years; in-situ carcinoma of cervix or breast treated and disease-free ≥3 years; superficial bladder cancer treated and disease-free ≥3 years; completely resected primary malignancy in complete remission ≥5 years.
  • Unstable angina and/or myocardial infarction within 1 year prior to screening.
  • Congestive heart failure of NYHA Class III or IV within 1 year prior to screening.
  • Thromboembolism, pulmonary embolism, or clinically significant bleeding diathesis within 6 months prior to screening.
  • Hypoxemia, clinically significant pleural effusion, or abnormal ECG findings within 6 months prior to screening.
  • Stroke (ischemic or hemorrhagic) within 6 months prior to screening.
  • Positive HBsAg; positive anti-HCV (eligible if HCV RNA negative); known HIV infection; or active neurological autoimmune/inflammatory diseases (e.g., Guillain-Barré syndrome, ALS).
  • Recurrent or symptomatic ventricular tachycardia, or atrial fibrillation with rapid ventricular response despite therapy within 3 months prior to screening.
  • Severe or uncontrolled active infection requiring systemic therapy at screening.
  • Rapidly progressive disease or otherwise unsuitable for study participation, per investigator judgment.
  • Pregnant or breastfeeding women.
  • Known hypersensitivity to investigational product components.
  • Participation in another investigational study within 4 weeks prior to screening.
  • Receipt of systemic corticosteroids at therapeutic doses within 7 days prior to leukapheresis (≤7.5 mg/day prednisone equivalent is permitted).
  • Receipt of immunosuppressive agents within 7 days prior to leukapheresis.
  • Receipt of antibody-based therapies (e.g., belimumab, rituximab, anifrolumab) within 4 weeks prior to leukapheresis.

Inclusion Criteria for CRC01 Infusion:

  • No clinically significant worsening of organ function after screening.

  • If any of the following adverse events related to lymphodepleting chemotherapy exceed Grade 1 or worsen compared with screening, CRC01 infusion must be delayed:

    • Requirement for supplemental oxygen
    • New arrhythmia symptoms or clinically significant changes in cardiac function compared with screening
    • Hypotension requiring treatment

    • Active infection within 72 hours prior to the planned CRC01 infusion

      • If bacterial, viral, or fungal infection is documented, improvement of symptoms must be documented before infusion.
  • Women of childbearing potential must have a negative urine pregnancy test prior to infusion.
  • If CRC01 infusion is delayed for more than 2 weeks after lymphodepleting chemotherapy, administration may proceed only with approval from the sponsor's medical monitor.
  • No receipt of therapeutic doses of systemic corticosteroids or immunosuppressive agents within 7 days prior to CRC01 infusion. (Prednisone ≤7.5 mg/day or equivalent is permitted.)
  • No receipt of antibody-based therapies (e.g., belimumab, rituximab, anifrolumab) within 4 weeks prior to CRC01 infusion.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    CRC01

    Participants with lupus nephritis will receive a single intravenous infusion of CRC01 (autologous anti-CD19 CAR-T cells) following lymphodepleting pre-conditioning chemotherapy.

    Biological: CRC01

Interventions

  • BiologicalCRC01

    Autologous T lymphocytes genetically modified to express anti-CD19 chimeric antigen receptor (CAR). Administered as a single intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Phase 1 Study: To evaluate the tolerability of CRC01 in patients with severe refractory autoimmune disease (systemic lupus erythematosus), and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D)

    Safety and tolerability will be assessed by: 1\. Number of participants with dose-limiting toxicities (DLTs) within 28 days after CRC01 infusion, as assessed by CTCAE v5.0 and ASTCT consensus criteria.

    Time frame: 28 day

  2. Phase 1 Study: To evaluate the tolerability of CRC01 in patients with severe refractory autoimmune disease (systemic lupus erythematosus), and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D)

    Safety and tolerability will be assessed by: 2\. Determination of the maximum tolerated dose (MTD) defined as the highest dose level at which ≤1 of 6 participants experience a DLT.

    Time frame: 28 day

  3. Phase 1 Study: To evaluate the tolerability of CRC01 in patients with severe refractory autoimmune disease (systemic lupus erythematosus), and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D)

    Safety and tolerability will be assessed by: 3\. Determination of the recommended Phase 2 dose (RP2D) based on incidence of DLTs, safety profile, and investigator/sponsor assessment.

    Time frame: 28 day

  4. Phase 2 Study: To evaluate the efficacy of CRC01 by assessing Complete Renal Response (CRR)

    Complete Renal Response (CRR): Defined as meeting all of the following criteria: 1\. 24-hour urine protein ≤0.5 g, or urine protein-to-creatinine ratio (UPCR) ≤0.5. If a 24-hour urine collection is available and meets adequacy criteria, 24-hour urine protein assessment takes precedence. If the 24-hour urine collection is inadequate or not performed, UPCR will be used for evaluation.

    Time frame: 24 weeks

  5. Phase 2 Study: To evaluate the efficacy of CRC01 by assessing Complete Renal Response (CRR)

    Complete Renal Response (CRR): Defined as meeting all of the following criteria: 2\. eGFR ≥60 mL/min/1.73m², or a decrease in eGFR ≤20% compared with the pre-flare value.

    Time frame: 24 weeks

  6. Phase 2 Study: To evaluate the efficacy of CRC01 by assessing Complete Renal Response (CRR)

    Complete Renal Response (CRR): Defined as meeting all of the following criteria: 3\. No use of rescue medication for systemic lupus erythematosus (SLE). (Use of corticosteroids equivalent to ≤7.5 mg/day prednisone is permitted.)

    Time frame: 24 weeks

Secondary outcomes

  1. Complete Renal Response (CRR) or Partial Renal Response (PRR) at each assessment Visit

    PRR is defined as ≥50% reduction in UPCR compared with baseline.

    Time frame: Up to Week 52

  2. Change From Baseline in Urine Protein-to-Creatinine Ratio (UPCR)

    Change from baseline in UPCR measured in urine (mg/mg)

    Time frame: up to Week 52

  3. Change From Baseline in Serum Creatinine

    Change from baseline in serum creatinine. Unit of measure (mg/dL)

    Time frame: up to Week 52

  4. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)

    Change from baseline in eGFR. Unit of measure: mL/min/1.73 m²

    Time frame: up to Week 52

  5. Change from baseline in UPCR, serum creatinine, urine protein, and eGFR

    Composite evaluation of renal parameters including UPCR (mg/mg)

    Time frame: up to Week 52

  6. Time to achieve UPCR ≤0.5

    Time from baseline to first achievement of UPCR ≤0.5.

    Time frame: Up to Week 52

  7. Change from baseline in SLEDAI-2K scores

    Evaluation of change in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)

    Time frame: Weeks 12, 24, and 52

  8. Change From Baseline in Physician's Global Assessment at Week 12

    Change in Physician's Global Assessment (PGA; scale 0-3)

    Time frame: Week 12

  9. Change From Baseline in Physician's Global Assessment at Week 24

    Change in Physician's Global Assessment (PGA; scale 0-3)

    Time frame: Week 24

  10. Change From Baseline in Physician's Global Assessment at Week 52

    Change in Physician's Global Assessment (PGA; scale 0-3)

    Time frame: Week 52

  11. Achieving LLDAS at each assessment Visit

    Percentage of participants achieving Low Lupus Disease Activity State (LLDAS)

    Time frame: Weeks 12, 24, and 52

  12. Change from baseline in SF-36 scores

    Change in health-related quality of life assessed by Short Form Health Survey-36 (SF-36)

    Time frame: Weeks 12, 24, and 52

  13. Change from screening in immunology parameters

    Composite evaluation of immunology markers including C3, C4 (mg/dL), anti-dsDNA antibody (IU/mL), and autoantibody titers (ANA, Anti-Sm, Anti-Ro 52/60, Anti-La). Each marker will be summarized separately and reported by its corresponding unit of measure.

    Time frame: up to Week 52

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07364396
Lead sponsor
Curocell Inc.
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Feb 2026 (estimated)
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Jan 23, 2026

Study contacts

Sihong Choi
Contact
sihong.choi@curocellbtx.com
+821033848516

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lupus Nephritis→

Other studies from this sponsor

Curocell Inc.

Start the discussion